← Back to Search

Monoclonal Antibodies

Radioimmunotherapy for Chronic Lymphocytic Leukemia

Phase 1
Waitlist Available
Research Sponsored by Corixa Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients must not have received more than 4 prior therapies. This includes both chemotherapy and biologic therapy
Patients must fulfill the criteria for the diagnosis of intermediate-risk B-cell CLL or high-risk B-cell CLL
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is testing a new cancer treatment to see if it is safe and effective.

Who is the study for?
This trial is for adults with intermediate to high-risk B-cell Chronic Lymphocytic Leukemia (CLL) who have had at least one prior treatment but no more than four. They must show certain blood cell counts, good kidney and liver function, a decent physical status, and not be pregnant or nursing. Those with serious illnesses, HIV, recent chemotherapy or immunosuppressants use are excluded.Check my eligibility
What is being tested?
The study tests the safety and effectiveness of Iodine-131 Anti-B1 Antibody in CLL patients. It aims to find the highest dose that can be administered without causing severe side effects by observing its impact on participants.See study design
What are the potential side effects?
Potential side effects include reactions related to iodine exposure such as thyroid issues, nausea, fatigue; immune responses due to antibody presence like fever or weakness; and typical risks associated with radiation therapy.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have had 4 or fewer previous cancer treatments.
Select...
My condition is diagnosed as intermediate or high-risk B-cell CLL.
Select...
My cancer did not respond or got worse after chemotherapy or biologic therapy.
Select...
I have been treated with a medicine related to purine nucleoside.
Select...
I can care for myself but may need occasional help, and my doctor expects me to live at least 3 more months.
Select...
My leukemia cells test positive for CD20.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Corixa CorporationLead Sponsor
9 Previous Clinical Trials
560 Total Patients Enrolled
GlaxoSmithKlineIndustry Sponsor
4,742 Previous Clinical Trials
8,066,331 Total Patients Enrolled

Media Library

Iodine-131 Anti-B1 Antibody (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00022880 — Phase 1
Chronic Lymphocytic Leukemia Research Study Groups:
Chronic Lymphocytic Leukemia Clinical Trial 2023: Iodine-131 Anti-B1 Antibody Highlights & Side Effects. Trial Name: NCT00022880 — Phase 1
Iodine-131 Anti-B1 Antibody (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00022880 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To be a part of this research, what are the basic requirements a person must meet?

"This clinical trial is looking for 30 people with leukemia between the ages of 18 and 0. Most notable, candidates are required to meet the following criteria: Patients must have a Karnofsky Performance status of at least 60% and an anticipated survival of at least 3 months., Patients must fulfill the criteria for the diagnosis of intermediate-risk B-cell CLL or high-risk B-cell CLL, The bone marrow aspirate must demonstrate that greater than or equal to 30% of all nucleated cells are lymphoid., Patients must have evidence that their leukemic lymphocytes express the CD20 antigen., Patients must have been previously treated"

Answered by AI

Does the age limit for this research project exclude people in their early forties?

"The age limit to qualify for this trial is 18 years old. Out of the 2123 total trials, this one is unique in that it only includes patients who are 18 years old or younger."

Answered by AI

How does this treatment's safety record compare to other available options?

"Since this is a Phase 1 trial, there is only preliminary data supporting the safety of this treatment. Consequently, our team at Power has given it a 1."

Answered by AI

Are people with the ailment under study able to participate in the trial at this time?

"The study in question is not currently looking for candidates, as seen on clinicaltrials.gov. This site was last updated on June 23rd, 2005, and was posted on July 1st, 1999. However, there are many other trials (1570) that are currently looking for patients."

Answered by AI
~1 spots leftby Mar 2025